Equities

Assembly Biosciences Inc

Assembly Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.78
  • Today's Change-0.72 / -4.11%
  • Shares traded31.54k
  • 1 Year change+64.20%
  • Beta0.5891
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Assembly Biosciences Inc have a median target of 35.50, with a high estimate of 36.00 and a low estimate of 35.00. The median estimate represents a 111.56% increase from the last price of 16.78.
High114.5%36.00
Med111.6%35.50
Low108.6%35.00

Earnings history & estimates in USD

On Nov 07, 2024, Assembly Biosciences Inc reported 3rd quarter 2024 losses of -1.51 per share. This result exceeded the -2.02 consensus loss of the 2 analysts covering the company and exceeded last year's 3rd quarter results by 53.40%.
The next earnings announcement is expected on Mar 27, 2025.
Average growth rate+15.22%
Assembly Biosciences Inc reported annual 2023 losses of -13.38 per share on Mar 28, 2024.
Average growth rate+19.23%
More ▼

Revenue history & estimates in USD

Assembly Biosciences, Inc. had 3rd quarter 2024 revenues of 6.85m. This missed the 8.65m consensus estimate of the 2 analysts following the company.
Average growth rate+2.83%
Assembly Biosciences, Inc. had revenues for the full year 2023 of 7.16m.
Average growth rate+67.82%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.